



WENDEL Investissement will receive more than 400 million euros from the sale of its bioMérieux shares

The successful placement of bioMérieux shares, for which demand was more than five times greater than the number offered, allowed WENDEL Investissement and bioMérieux to opt for a launch price of 30 euros per share, at the high end of the range initially determined.

In the hypothesis that banks later exercise their supplemental allocation option, WENDEL Investissement will have sold all its shares and received a total of 414 million euros from its bioMérieux shares (before commissions paid to banks): 344 million euros from the sale of shares on the market, 60 million euros from the sale to a group of investors led by CIC Banque de Vizille, and 10 million euros in exceptional dividends.

Contacts:

Christine Dutreil Tel.: +33 (0)1 42 85 63 24 / E-mail: c.dutreil@wendel-investissement.com
Gérard Lamy Tel.: +33 (0)1 42 85 63 75 / E-mail: g.lamy@wendel-investissement.com